124 related articles for article (PubMed ID: 38450660)
1.
Dingiş Birgül Sİ; Kumari J; Tamhaev R; Mourey L; Lherbet C; Sriram D; Akdemir A; Küçükgüzel İ
J Biomol Struct Dyn; 2024 Mar; ():1-19. PubMed ID: 38450660
[TBL] [Abstract][Full Text] [Related]
2. Structural modification of a novel inhibitor for mycobacterium enoyl-acyl carrier protein reductase assisted by
Taira J; Nagano T; Kitamura M; Yamaguchi M; Sakamoto H; Aoki S
Int J Mycobacteriol; 2020; 9(1):12-17. PubMed ID: 32474482
[TBL] [Abstract][Full Text] [Related]
3. Piperazine derivatives: synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase and SAR studies.
Rotta M; Pissinate K; Villela AD; Back DF; Timmers LF; Bachega JF; de Souza ON; Santos DS; Basso LA; Machado P
Eur J Med Chem; 2015 Jan; 90():436-47. PubMed ID: 25461892
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
[TBL] [Abstract][Full Text] [Related]
5. Improvement of the novel inhibitor for Mycobacterium enoyl-acyl carrier protein reductase (InhA): a structure-activity relationship study of KES4 assisted by in silico structure-based drug screening.
Taira J; Umei T; Inoue K; Kitamura M; Berenger F; Sacchettini JC; Sakamoto H; Aoki S
J Antibiot (Tokyo); 2020 Jun; 73(6):372-381. PubMed ID: 32152525
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, In silico Molecular Docking and Pharmacokinetic Studies, In vitro Antimycobacterial and Antimicrobial Studies of New Imidozolones Clubbed with Thiazolidinedione.
Khan IH; Patel NB; Patel VM
Curr Comput Aided Drug Des; 2018; 14(4):269-283. PubMed ID: 29766819
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.
Izumizono Y; Arevalo S; Koseki Y; Kuroki M; Aoki S
Eur J Med Chem; 2011 May; 46(5):1849-56. PubMed ID: 21397998
[TBL] [Abstract][Full Text] [Related]
8. Mandelic acid-based spirothiazolidinones targeting M. tuberculosis: Synthesis, in vitro and in silico investigations.
Trawally M; Demir-Yazıcı K; Dingiş-Birgül Sİ; Kaya K; Akdemir A; Güzel-Akdemir Ö
Bioorg Chem; 2022 Apr; 121():105688. PubMed ID: 35189443
[TBL] [Abstract][Full Text] [Related]
9.
Yadav S; Mandal H; Saravanan V; Das P; Singh SK
J Biomol Struct Dyn; 2021 Oct; 39(16):6056-6069. PubMed ID: 32762412
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of
Mahfuz AMUB; Stambuk Opazo F; Aguilar LF; Iqbal MN
J Biomol Struct Dyn; 2022 Jun; 40(9):4021-4037. PubMed ID: 33251968
[TBL] [Abstract][Full Text] [Related]
11. X-ray crystal structure of Mycobacterium tuberculosis beta-ketoacyl acyl carrier protein synthase II (mtKasB).
Sridharan S; Wang L; Brown AK; Dover LG; Kremer L; Besra GS; Sacchettini JC
J Mol Biol; 2007 Feb; 366(2):469-80. PubMed ID: 17174327
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade.
Holas O; Ondrejcek P; Dolezal M
J Enzyme Inhib Med Chem; 2015; 30(4):629-48. PubMed ID: 25383419
[TBL] [Abstract][Full Text] [Related]
13. A rational approach to identify inhibitors of Mycobacterium tuberculosis enoyl acyl carrier protein reductase.
Chhabria MT; Parmar KB; Brahmkshatriya PS
Curr Pharm Des; 2013; 19(21):3878-83. PubMed ID: 23477735
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, structural characterization by IR, (1) H, (13) C, (15) N, 2D-NMR, X-ray diffraction and evaluation of a new class of phenylaminoacetic acid benzylidene hydrazines as pfENR inhibitors.
Samal RP; Khedkar VM; Pissurlenkar RR; Bwalya AG; Tasdemir D; Joshi RA; Rajamohanan PR; Puranik VG; Coutinho EC
Chem Biol Drug Des; 2013 Jun; 81(6):715-29. PubMed ID: 23398677
[TBL] [Abstract][Full Text] [Related]
15. Discovery of InhA inhibitors with anti-mycobacterial activity through a matched molecular pair approach.
Kanetaka H; Koseki Y; Taira J; Umei T; Komatsu H; Sakamoto H; Gulten G; Sacchettini JC; Kitamura M; Aoki S
Eur J Med Chem; 2015 Apr; 94():378-85. PubMed ID: 25778993
[TBL] [Abstract][Full Text] [Related]
16. Enoyl ACP reductase as effective target for the synthesized novel antitubercular drugs: a-state-of-the-art.
Joshi SD; Dixit SR; More UA; Aminabhavi TM; Kulkarni VH; Gadad AK
Mini Rev Med Chem; 2014; 14(8):678-93. PubMed ID: 25138092
[TBL] [Abstract][Full Text] [Related]
17. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
[TBL] [Abstract][Full Text] [Related]
18. Novel 4-aminoquinolines: Synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase, antitubercular activity, SAR, and preclinical evaluation.
Paz JD; Denise de Moura Sperotto N; Ramos AS; Pissinate K; da Silva Rodrigues Junior V; Abbadi BL; Borsoi AF; Rambo RS; Corso Minotto AC; da Silva Dadda A; Galina L; Macchi Hopf FS; Muniz MN; Borges Martinelli LK; Roth CD; Madeira Silva RB; Perelló MA; de Matos Czeczot A; Neves CE; Duarte LS; Leyser M; Dias de Oliveira S; Bizarro CV; Machado P; Basso LA
Eur J Med Chem; 2023 Jan; 245(Pt 1):114908. PubMed ID: 36435016
[TBL] [Abstract][Full Text] [Related]
19. Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis.
Khalifa A; Khalil A; Abdel-Aziz MM; Albohy A; Mohamady S
Bioorg Chem; 2023 Sep; 138():106591. PubMed ID: 37201321
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
Lokesh BVS; Prasad YR; Shaik AB
Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
